Main characteristics of 439 patients with ET
| Characteristic . | Data . |
|---|---|
| Sex, no. (%) | |
| Male | 175 (40) |
| Female | 264 (60) |
| Median age at diagnosis, y (range) | 54 (10-93) |
| Median WBC (range), × 109/L | 8.7 (1.7-23) |
| Median HB (range), g/dL | 14 (9.7-17.6) |
| Median HCT (range), % | 42 (30-54) |
| Median PLT (range), × 109/L | 784 (145-2149) |
| JAK2 V617F (%)* | 151 (55) |
| Heterozygous | 147 (97) |
| Homozygous | 4 (3) |
| Time from diagnosis to referral, no. (%) | |
| 0 y | 189 (43) |
| 1-2 y | 30 (7) |
| 3-4 y | 50 (11) |
| 5-6 y | 46 (10) |
| 7-10 y | 61 (14) |
| More than 10 y | 65 (15) |
| History of vascular events, no. (%) | 129 |
| AMI | 38 (29) |
| Stroke/TIA | 28 (22) |
| PAT | 22 (17) |
| VTE | 41 (32) |
| Treated patients, no. (%) | |
| No treatment | 120 (27) |
| Hydroxyurea | 229 (52) |
| Antiplatelets | 209 (47) |
| Vascular events in follow-up, no. (%) | 78 |
| AMI | 19 (24) |
| Stroke/TIA | 21 (27) |
| PAT | 11 (14) |
| VTE | 27 (35) |
| Characteristic . | Data . |
|---|---|
| Sex, no. (%) | |
| Male | 175 (40) |
| Female | 264 (60) |
| Median age at diagnosis, y (range) | 54 (10-93) |
| Median WBC (range), × 109/L | 8.7 (1.7-23) |
| Median HB (range), g/dL | 14 (9.7-17.6) |
| Median HCT (range), % | 42 (30-54) |
| Median PLT (range), × 109/L | 784 (145-2149) |
| JAK2 V617F (%)* | 151 (55) |
| Heterozygous | 147 (97) |
| Homozygous | 4 (3) |
| Time from diagnosis to referral, no. (%) | |
| 0 y | 189 (43) |
| 1-2 y | 30 (7) |
| 3-4 y | 50 (11) |
| 5-6 y | 46 (10) |
| 7-10 y | 61 (14) |
| More than 10 y | 65 (15) |
| History of vascular events, no. (%) | 129 |
| AMI | 38 (29) |
| Stroke/TIA | 28 (22) |
| PAT | 22 (17) |
| VTE | 41 (32) |
| Treated patients, no. (%) | |
| No treatment | 120 (27) |
| Hydroxyurea | 229 (52) |
| Antiplatelets | 209 (47) |
| Vascular events in follow-up, no. (%) | 78 |
| AMI | 19 (24) |
| Stroke/TIA | 21 (27) |
| PAT | 11 (14) |
| VTE | 27 (35) |
HB indicates hemoglobin level; HCT, hematocrit; PLT, platelet count; AMI, acute myocardial infarction; TIA, cerebral transient ischemic attack; PAT, peripheral arterial thrombosis; and VTE, venous thromboembolism.
Percentage calculated on 277 patients with Jak2 mutational status evaluated.